1. MARKETS
  2. SECTOR : HEALTHCARE
  3. INDUSTRY : HEALTHCARE SUPPLIES
  4. POLY MEDICURE LTD.
Poly Medicure Ltd.
NSE: POLYMED | BSE: 531768

Poly Medicure Live Share Price Today, Share Analysis and Chart

Expensive Performer
BasketIn 3 Starfolio Baskets
aboutPoly Medicure Ltd. (Polymed) is an Indian medical device manufacturer and exporter, specialising in high-quality medical disposables and equipment. Established in 1995, the company has developed a diverse portfolio of over 200 products across therape... Read More
Ask AI about Poly Medicure
1486.9037.40(2.58%)

29.00% Fall from 52W High

59,367
NSE+BSE Volume

NSE 02 Nov, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Poly Medicure is on 05 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
43.1 / 100
Expensive PerformerThese stocks have medium quality and momentum.Their expensive valuations suggest cautionView SimilarEmbed DVM
Analyst Price Target
-

15

S

12

W

3

O

0

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

Medium rank

10Positive13Negative

43.5%Pass in checklist

045
55
100

PE Valuation Check

Right Now
Undervalued
41%
1 Year Forward
Undervalued
84.1%
INSIGHTPoly Medicure is undervalued at both current PE and future earnings estimates.

Poly Medicure Stock Price Analysis

Day Price Range

2.6% 1 Day return
1486.9 (LTP)
1,443.41,495.3
LowHigh

Week Price Range

3.0% 1 Week return
1486.9 (LTP)
1,401.51,495.3
LowHigh

Month Price Range

-9.2% 1 Month return
1486.9 (LTP)
1,401.51,649.9
LowHigh

52 Week Price Range

-25.6% 1 Year return
1486.9 (LTP)
1,1822,094.3
LowHigh
View full Price History/Seasonality

Poly Medicure Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Poly Medicure's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
31.8
AVG. ESTIMATE
41.4
LOW ESTIMATE
37.4
HIGH ESTIMATE
44.3
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 30.5% in FY27

Consensus Recommendation

6 ANALYST Recommendations
BUY

The consensus recommendation from 6 analysts for Poly Medicure is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Poly Medicure Technical Analysis

Poly Medicure EMA & SMA

Bearish-6
1 bullish, 7 bearish
Bullish1
Bearish7
5 Day1471.0
10 Day1486.9
12 Day1495.8
20 Day1530.9
26 Day1552.9
50 Day1602.7
100 Day1620.3
200 Day1651.5

Poly Medicure Delivery And Volume

Daily Avg. Delivery Volume %
02 Nov, 202650.4%
Week55.9%
Month56.4%

Poly Medicure Active Candlesticks

Long Line Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Poly Medicure Resistance and Support

1475.20
Pivot
First Resistance1507
Second Resistance1527.1
Third Resistance1558.9
First Support1455.1
Second Support1423.3
Third Support1403.2
Day RSI38.1
Day MACD-57
Day MFI23.5
Day MACD Signal Line-55.1

Poly Medicure Beta

1 Month0.3
1 Year0.9
3 Month0.4
3 Year0.8

Poly Medicure Price Change Analysis

↓-9.2%
Over 1 Month
LowHigh
1401.51649.9
↓-12.6%
Over 3 Months
LowHigh
1401.51913.7
↓-1.7%
Over 6 Months
LowHigh
13001913.7
↓-25.6%
Over 1 Year
LowHigh
11822094.3
All Technicals →

Poly Medicure Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Ezekiel Global Business Solutions LlpPromoter12,361,32012.2 %
Nirmala Vinodkumar DagaPublic1,081,6691.1 %
Quant Mutual Fund - Quant Small Cap FundDii4,621,8144.6 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Poly Medicure Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
SMALLCAP WORLD FUND INCBulkSell16 Jan 20261645950,000NSE
SMALLCAP WORLD FUND INCBulkSell16 Jan 20261645887,064BSE
GOLDMAN SACHS (SINGAPORE) PTE - ODIBlockSell09 Oct 20251902264,142NSE
GOLDMAN SACHS BANK EUROPE SE - ODIBlockPurchase09 Oct 20251902264,142NSE
LIGHTHOUSE INDIA III EQUITY INVESTORS LIMITEDBulkSell21 Jun 20241950.032,276,269NSE
LIGHTHOUSE INDIA III EQUITY INVESTORSLIMITEDBulkSell21 Feb 20241550.061,290,939BSE
BNP PARIBAS ARBITRAGEBlockSell25 Jan 20241450.70101,686BSE
SOCIETE GENERALEBlockPurchase25 Jan 20241450.70101,686BSE
NILAYKUMAR VINODKUMAR DAGABulkPurchase27 Mar 2017228.35567,066BSE
NIRAJKUMAR VINODKUMAR DAGA NROBulkSell27 Mar 2017228.35567,076BSE
All deals
All insider trades

Poly Medicure Corporate Actions

Poly Medicure Dividend history and yield

Poly Medicure dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Poly Medicure dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
128 Aug 2026
3.5FINAL29 Aug 2026Equity Share
218 Sep 2025
3.5FINAL18 Sep 2025Equity Share
319 Sep 2024
3FINAL-Equity Share
421 Sep 2023
3FINAL-Equity Share
516 Sep 2022
2.5FINAL-Equity Share

Poly Medicure Bonus shares

Poly Medicure bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
124 Mar 2017
1:128 Mar 2017
209 Jul 2013
1:110 Jul 2013
326 Mar 2010
1:129 Mar 2010

Poly Medicure Board Meetings

Poly Medicure past and upcoming board meetings.

#Ex-Date
PurposeNotes
105 Nov 2026
Quarterly Results-
207 Aug 2026
Quarterly Results-
325 May 2026
Audited Results & Final Dividend-
405 Feb 2026
Quarterly Results-
508 Nov 2025
Quarterly Results-

Poly Medicure Stock Split

Poly Medicure stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
102 Feb 2015
105-
All Corporate Actions

Poly Medicure Research Reports

Poly Medicure research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
111 Aug 2026Joindre Capital Services-1869.4Results Update--20.46%pdf
201 Jun 2026Joindre Capital Services-1321.4Results Update-12.52%pdf
316 Mar 2026Joindre Capital Services1489.21241.4Buy19.96%19.78%pdf
426 Dec 2024FundsIndia30162619.8Buy15.12%-43.24%pdf
524 Jul 2024ICICI Securities Limited
Target
19402023.1Hold-4.11%-26.5%pdf
All Reports of Poly

Poly Medicure Corporate Filings

Poly Medicure BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
31 Oct 2026
Poly Medicure Ltd - 531768 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of earnings call on Financial Results for the Quarter and Half -Year ended on September 30, 2026
PDF
29 Oct 2026
Poly Medicure Ltd - 531768 - Board Meeting Intimation for Intimation Of Notice Of Board Meeting To Be Held On 05Th November, 2026
Poly Medicure Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve a. The Unaudited Financial Results (Consolidated & Standalone) of the company for the Second Quarter and Half year ended on 30th September, 2026. b. To transact any other matter which the Board may deem fit.
PDF
13 Oct 2026
Poly Medicure Ltd - 531768 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
PDF
28 Sep 2026
Poly Medicure Ltd - 531768 - Closure of Trading Window
The Company Informed the Exchange about the Closure of Trading Window.
PDF
24 Sep 2026
Poly Medicure Ltd - 531768 - Intimation For The Schedule Of Investors/Analysts Call/Meet.
Enclosed
PDF
VIEW ALL

Poly Medicure DocumentsAsk MarketMind AI

Poly Medicure Earnings Call

Poly Medicure earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
14 Aug 2026Poly Medicure Ltd - 531768 - Analyst Investor Meet Call TranscriptLink
29 May 2026Poly Medicure Ltd - 531768 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
11 Feb 2026Poly Medicure Ltd - 531768 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
14 Nov 2025Poly Medicure Ltd - 531768 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
10 Nov 2025Poly Medicure Results Earnings Call for Q2FY26AudioVideo
view all

Poly Medicure Annual Reports

Poly Medicure financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link
2021Annual Report Mar-2021Link

Poly Medicure Credit Ratings

Poly Medicure credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
23 Jun 2026crisil ratingsPoly Medicure LimitedPoly Medicure Limited:Rating outlook revised to 'Positive'; Ratings Reaffirmed; Rated amount enhanced for Bank DebtLink
30 Mar 2025crisil ratingsPoly Medicure LimitedPoly Medicure Limited:Update on Poly Medicure LimitedLink
28 Mar 2025crisil ratingsPoly Medicure LimitedPoly Medicure Limited:Ratings reaffirmed at 'Crisil AA-/Stable/Crisil A1+'; Rated amount enhanced for Bank DebtLink
28 Feb 2024crisil ratingsPoly Medicure LimitedPoly Medicure Limited:Ratings reaffirmed at 'CRISIL AA-/Stable/CRISIL A1+'Link
26 Feb 2023crisil ratingsPoly Medicure LimitedPoly Medicure Limited:Update on Poly Medicure LimitedLink

Poly Medicure Investor Presentations

Poly Medicure investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
07 Aug 2026Poly Medicure Ltd - 531768 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
25 May 2026Poly Medicure Ltd - 531768 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
25 May 2026Poly Medicure Ltd - 531768 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
07 Mar 2026Poly Medicure Ltd - 531768 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
05 Feb 2026Poly Medicure Ltd - 531768 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Poly Medicure - Company Profile

Poly Medicure Management Structure

Poly Medicure management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Vishal BaidSenior Vice President(Corporate Sales.,Marketing)-Mar 26
Pankaj Kumar GuptaPresident - R & D-Mar 26
Mr. Naresh VijayvergiyaChief Financial Officer-Mar 26
Mr. Rahul GautamExecutive(Corporate Strategy)-Mar 26
Avinash ChandraCompany Secretary,Compliance Officer-Mar 26
Ravi PrakashDeputy Company Secretary-Mar 26
Mr. Abhinav GeraVice President(Human Resources)-Mar 26
Mr. Bijaya Singh RawatSenior General Manager(Production)-Mar 26
Mr. Sujit Kumar GuptaVice President(International Sales,Marketing)-Mar 26
Mr. Hemant BhallaVice President(Domestic Sales,Marketing)-Mar 26
Mr. Rakesh BothraVice President(Shipping & Logistics)-Mar 26
Mr. Surendra Singh RawatVice President(Management.,Quality)-Mar 26

Poly Medicure Board of Directors

Poly Medicure Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Himanshu BaidExecutive Director & MD2142.28Mar 25
Rishi BaidJoint MD & Executive Director2093.04Mar 25
Alessandro BalboniNon-Exec & Non-Independent Dir282.38Mar 25
Sonal MattooIndependent Non Exe. Director22.75Mar 25
Devendra Raj MehtaChairman(Non Exe)&Dir(Non-Ind)22.75Mar 25
Amit KhoslaIndependent Non Exe. Director21.75Mar 25
Jugal Kishore BaidNon Executive Director20.75Mar 25
Ambrish MithalIndependent Non Exe. Director20.5Mar 25
Vimal BhandariIndependent Non Exe. Director14.05Mar 25
Vishal GuptaIndependent Non Exe. Director9.5Mar 25
Avinash ChandraCompany Sec. & Compli. Officer-Mar 25
Website: www.polymedicure.com

About the company - Business Profile

Poly Medicure Ltd. (Polymed) is an Indian medical device manufacturer and exporter, specialising in high-quality medical disposables and equipment. Established in 1995, the company has developed a diverse portfolio of over 200 products across therapeutic areas such as infusion therapy, anaesthesia, oncology, urology, and gastroenterology. Polymed maintains a global presence, exporting to more than 125 countries, and operates with a strong focus on clinical engagement and international quality certifications.

Key Points

  • Key Facts:
    • Founded: 1995.
    • Headquarters: Faridabad, Haryana, India.
    • Stock Listing: Listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).
    • Primary Products: Infusion therapy, Renal care (dialysis), Anaesthesia, Urology, Gastroenterology, Cardiology, and Critical care consumables.
  • Operations and Resources:
    • Facilities: Operates 14 manufacturing plants across 5 countries, including India (multiple units in Faridabad, Jaipur, and Haridwar), China (Laiyang-Qingdao), Egypt (Assuit), and Italy (Amaro).
    • Capacity: Annual manufacturing capacity exceeds 1.8 billion devices.
    • R&D: Operates a dedicated R&D center in Faridabad with over 375 patents granted globally.
  • Privatization and Ownership:
    • The company is promoter-led, with the Promoter Group holding 62.4% as of December 31, 2025.
    • Institutional holding includes Foreign Portfolio Investors (9.4%) and Mutual Funds (8.1%).
  • Market Significance:
    • Polymed is a major exporter, recognized as the top exporter of plastic medical disposables from India for over a decade. It serves critical healthcare segments globally, including direct sales force presence in key European markets.
  • Sustainability and Innovation:
    • The company focuses on clinical engagement programs and international training to enhance MedTech adoption. Strategic acquisitions like PendraCare (Netherlands) and Citieffe (Italy) are intended to bolster capabilities in interventional cardiology and trauma/extremity fixation systems.
  • Business Model:
    • Polymed follows a vertically integrated model, from product development and R&D to in-house manufacturing and global distribution. It excels in high-volume, precision manufacturing of disposable medical devices.
  • Revenue Breakdown (FY 2024-25 Annual Numbers):
    • Revenue from Operations: ₹1,601.80 Crores (Standalone).
    • Net Profit (PAT): ₹331.33 Crores (Standalone).
    • Geographical Mix (Consolidated Q3 FY26):
      • India: 30%
      • Europe: 33%
      • Rest of World (RoW): 37%
  • Key Products and Technology:
    • Core Segments: Infusion Therapy (60% of 9M FY26 revenue), Renal (10%), and Others including Cardiology and Urology (30%).
    • Notable Advancement: The acquisition of Citieffe added unique navigation software for nailing systems and an MDR-cleared portfolio for trauma.
  • Partnerships and Acquisitions:
    • Citieffe (Italy): Acquisition closed in November 2025 to enter the Trauma and Extremity market.
    • PendraCare (Netherlands): Acquisition to enter the interventional cardiology consumable market.
    • Joint Venture: Operates a JV in Assuit, Egypt.
  • Employee Count and Trends:
    • Total employee base exceeded 3,500 as of late 2025 (up from 3,082 in March 2025). The company employs over 540 sales associates.
  • Major Subsidiaries:
    • Poly Medicure BV (Netherlands), PolyHealth Medical Inc. (USA), Plan 1 Health SRL (Italy), and Poly Medicure (Laiyang) Co. Ltd (China).
  • Strategic Initiatives and Future Outlook:
    • Expansion: Undertaking expansion with 4 new plants in Faridabad and Jaipur.
    • Capital Raising: Raised ₹1,000 Crores through a QIP in 2024 to fund growth and acquisitions.
    • Future Focus: Transitioning from a "Preferred Supplier" to a "Solutions Partner," targeting deeper penetration in cardiology, critical care, and trauma markets by 2027-2028.

References

  1. Annual Report May 2025
  2. Investor Presentation Feb 2026
  3. Investor Presentation Nov 2025
  4. Annual Report May 2024

Poly Medicure FAQ

Poly Medicure today is trading in the green, up by 2.58% at ₹1,486.9.
Poly Medicure is currently trading up 2.58% on an intraday basis. In the past week the stock rose 2.97%. Stock has been down 12.64% in the past quarter and fell 25.64% in the past year. You can view this in the share price history/seasonality section.
Poly Medicure is listed on NSE with the ticker POLYMED and on BSE as 531768. It's currently trading on NSE at a share price of ₹1,486.9 and on BSE with a share price of ₹1,480.1.
The market cap of Poly Medicure is ₹15,071.44 Cr. as of Nov 02, 2026.
Poly Medicure announced a FINAL dividend of 70% which equals ₹3.5 in Aug 28, 2026.The last three ex-dates for Poly Medicure were Sep 18, 2025, Sep 19, 2024 and Sep 21, 2023. To view the full dividend history of Poly Medicure click here.
Poly Medicure has undergone 1 stock split and announced bonus shares 3 times since its BSE/NSE listing. The latest announcement for Poly Medicure stock split was on Feb 02, 2015 at a ratio of 10:5 and the last bonus share announcement was on Mar 24, 2017 at a ratio of 1:1.
Poly Medicure reported ₹558.78 Cr. in revenue, ₹86.03 Cr. in net profit, and ₹158.51 Cr. in EBITD as of Aug 07, 2026 for Q1 FY26-27.
According to the predictions of 6 analysts, the share price prediction for Poly Medicure is ₹1,858.17 with an upside of 25%.
The PE ratio of Poly Medicure is 47.83 as of Nov 02, 2026.
The PB ratio of Poly Medicure is 4.72 as of Nov 02, 2026.
You can view the latest analyst reports on the Poly Medicure reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×